Join

Compare · DXCM vs SRDX

DXCM vs SRDX

Side-by-side comparison of DexCom Inc. (DXCM) and Surmodics Inc. (SRDX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both DXCM and SRDX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • DXCM is the larger of the two at $28.11B, about 47.0x SRDX ($598.4M).
  • Over the past year, DXCM is down 14.9% and SRDX is up 47.8% - SRDX leads by 62.8 points.
  • DXCM has hit the wire 26 times in the past 4 weeks while SRDX has been quiet.
  • DXCM has more recent analyst coverage (25 ratings vs 7 for SRDX).
PerformanceDXCM+8.05%SRDX+47.83%
2025-12-22+0.00%2026-06-05
MetricDXCMSRDX
Company
DexCom Inc.
Surmodics Inc.
Price
$72.84+0.38%
$42.99+0.33%
Market cap
$28.11B
$598.4M
1M return
+20.73%
+52.83%
1Y return
-14.94%
+47.83%
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NASDAQ
NASDAQ
IPO
2005
1998
News (4w)
26
0
Recent ratings
25
7
DXCM

DexCom Inc.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

SRDX

Surmodics Inc.

Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The Vitro Diagnostics segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. Surmodics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

Latest DXCM

Latest SRDX